Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2016-10-03 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 2 to Form S-1 Registration Statement filed with the SEC, dated October 3, 2016. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities being registered (common stock and warrants), offering price, underwriting, risk factors, business overview, management, and other typical contents of a registration statement prospectus. This is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration for an offering. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2016-10-03 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details an amendment to a consulting agreement with an interim Chief Operating Officer, including compensation terms and conditions. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document focuses on a management-related contractual update, which aligns with announcements about changes or arrangements involving senior management. Therefore, the most appropriate classification is 'Board/Management Information (MANG)'. The document length is 3540 characters, which is consistent with a typical 8-K filing for management changes or agreements, not a full report or announcement of a report publication.
2016-09-29 English
FWP
Regulatory Filings Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) filed pursuant to Rule 433, dated September 20, 2016. It provides an update on a Phase 1 clinical trial for a biotechnology company, AmpliPhi Biosciences. The text includes a press release with clinical trial progress and safety results, forward-looking statements, and references to a registration statement on Form S-1. There are no financial statements, earnings data, or management discussion of financial results. The document is a communication related to a securities offering, supplementing a registration statement, and is not a financial report, earnings release, or management report. It is a regulatory filing related to securities offering disclosures and clinical trial updates. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6597 characters) and content confirm it is not a brief announcement or a full report but a detailed regulatory communication.
2016-09-20 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated September 14, 2016. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities being registered (common stock and warrants), offering price, underwriting, risk factors, and company overview. This is a typical filing for a company's initial or follow-on public offering registration, not a financial report, earnings release, or management discussion. The document is not an announcement of a report but the actual registration statement amendment. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including registration statements for securities offerings.
2016-09-13 English
Regulatory Filings 2016
Regulatory Filings
2016-09-09 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus describing the offering of common stock and warrants, details about the company, risk factors, use of proceeds, and underwriting information. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual filing, not just an announcement or notice.
2016-09-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.